By continuing browsing, you agree to the storing of cookies on your device to enhance your site experience and for analytical purposes. To learn more about how we use the cookies, please see our Cookie Policy.
Overview
MediWound is a biopharmaceutical company that develops, manufactures and commercializes novel, cost effective, biotherapeutic solutions for tissue repair and regeneration.
Our strategy leverages our enzymatic technology platform, focusing on next-generation therapies for burn care, wound care and tissue repair.
NexoBrid, our commercial orphan biological product for eschar removal of severe thermal burns, is a bromelain-based biological product containing a sterile mixture of proteolytic enzymes that selectively removes burn eschar within four hours and does not harm surrounding viable tissue.
Nexobrid is FDA approved and currently marketed in the European Union as well as in other International markets such as India, Japan and Switzerland. It is supported by the U.S. Biomedical Advanced Research and Development Authority (BARDA). It is due to begin US distribution in early 2023.
EscharEx, our next-generation bioactive topical therapy for debridement of chronic and hard-to-heal wounds is a product candidate in advanced stages of development. In two Phase 2 studies EscharEx was well-tolerated and has demonstrated safety and efficacy in the debridement of various chronic and other hard-to-heal wounds, with only a few daily applications.
MW005, our topical biological drug for the treatment of low risk Basal Cell Carcinoma (BCC), is a clinical-stage product candidate under development.
Our Culture
"At MediWound, our talented team of professionals transform great ideas into reality. Our goal is to elevate the standard of care for our patients, resulting in a much better quality of life"
"I take enormous pleasure in knowing that my goal of making NexoBrid available to all patients has come to fruition, changing burn care for thousands of patients worldwide. For me, as a physician, to be able to leave this footprint in medicine is the greatest possible reward"
The Total Solution
MediWound has extensive history and experience developing, manufacturing, and commercializing non-surgical, regenerative solutions
In-house Expertise
State of the Art Facility
Wide global network
Our Team
Chief Executive Officer
Chief Medical Officer
Founder & Medical Director
EVP of Strategy and Corporate Development
Chief R&D Officer
Chief Operating Officer
Chief Financial Officer
Executive Vice President & General Counsel
VP of European Operations
VP Plant Manager
VP Clinical Affairs
VP Finance
VP R&D
Director of Regulatory Affairs
VP Quality
Chairman of the Board of Directors
Board Member
Board Member
Board Member
Board Member
Board Member
Board Member
Board Member
Co-founder and CEO of Equashield, a leading global provider of hazardous drug compounding technologies
Venture Partner at aMoon, Israel’s largest HealthTech VC fund
Chief of Surgery at Mount Sinai West Hospital in New York, practices as a senior vascular surgeon
Testimonials
Careers
Just us as we seek cure and advance care. Together we can improve patient outcomes and the standard of care.
"At MediWound, our talented team of professionals transform great ideas into reality. Our goal is to elevate the standard of care for our patients, resulting in a much better quality of life"
Chief Executive Officer
“It is a privilege to take on this role during such an exciting and transformative time for MediWound. I look forward to working with this outstanding management team as we focus our efforts on advancing our clinical pipeline. I am excited to be part of a company that will meaningfully improve the lives of millions of patients worldwide.”
Chief Medical Officer
"I take enormous pleasure in knowing that my goal of making NexoBrid available to all patients has come to fruition, changing burn care for thousands of patients worldwide. For me, as a physician, to be able to leave this footprint in medicine is the greatest possible reward"
Founder & Medical Director
Lior is one of our co‑founders and has served as our Chief Medical Technology Officer since 2001 and served as a member of our board of directors from 2001 to 2013. Since 2001, Dr. Rosenberg has headed the unit for Cleft Lip Palate and Craniofacial Deformities at Soroka University Medical Center and Meir Medical Centers in Beer Sheva and Kfar Saba, Israel, respectively. Since 1987, he has served as a Full Professor of plastic surgery at the Ben‑Gurion University Medical School in Beer Sheva, Israel. He also serves as the Chairman of the Burn Disaster Committee for the International Society of Burn Injuries and the Israeli Ministry of Health. From 1987 to 2012, Dr. Rosenberg served as the chairman of the Department of Plastic Surgery and Burn Unit at Soroka University Medical Center in Beer Sheva, Israel. He is a founding member of the Israeli Burn Association and the Mediterranean Burn Council, a member of the American Burn Association and a national representative at the European Burn Association. Dr. Rosenberg holds a M.D. degree from Tel‑Aviv University, Israel and a Professor of Plastic Surgery degree from the Ben Gurion University, Israel.
EVP of Strategy and Corporate Development
Mr. Wolfenson co-founded and is also CEO of vTail Healthcare Telecommunications, a healthcare-wide digital platform with an initial focus on the advanced wound care market. He also recently served as a key Strategic Advisor to Origin, Inc. on the development of their Phase III-ready IonoJetTM technology with an initial indication of diabetic foot ulcers. Mr. Wolfenson is currently on the Board of Directors at SANO Diagnostics, after having served as their CEO. SANO Diagnostics is a point-of-care inflammation diagnostic platform with initial focus on chronic wounds. Mr. Wolfenson spent 13 years at Derma Sciences in roles of increasing responsibility, helping to build the company’s advanced wound care business prior to its acquisition by Integra Life Sciences. He began his career as an analyst at Accenture before moving on to roles at Bristol Myers Squibb. Mr. Wolfenson holds a Master of Business Administration from the Stephen M. Ross School of Business, University of Michigan. He holds a Bachelor of Arts in Economics, & Pre-Med from Franklin & Marshall College.
"At MediWound, science, technological innovation and deep industry knowledge expands our portfolio with new bio-therapeutic solutions for unmet medical needs"
Chief R&D Officer
Chief Operating Officer
"In MediWound, we harness innovation, commitment, dedication and determination to change treatment paradigms to help patients’ in their times of pain. To see their relief is the most rewarding thing for us to cherish. It keeps driving us every single day"
Chief Financial Officer
"Creativity is thinking up new things. Innovation is doing new thing. At MediWound, we are privileged to have both, allowing us to improve our patients' lives and the standard of care."
Executive Vice President & General Counsel
VP of European Operations
"Establishing a state of the art cGMP sterile facility that takes the pineapple stem and makes it a pharmaceutical drug is a life accomplishment"
VP Plant Manager
“Clinical trials are important for discovering new treatments for diseases, as well as new ways to detect, diagnose, and reduce the chance of developing diseases. I’m proud to be part of all discoveries achieved in the last 20 years in the clinical development of our products and having new therapies available to patients”
VP Clinical Affairs
"I have the privilege to work to grow and develop with the company throughout the years, from a small startup to an established publicly traded company. The level of professional, commitment and high excellence of the company together with the way we improve patients’ lives is what drives me"
VP Finance
"Deep and robust foundations, are the key to every solid building. I am proud to lead the pre-clinical as well as the Chemistry, Manufacturing and Controls (CMC) development at MediWound. By a team work, my group is establishing the foundations for turning vision to reality"
VP R&D
"Regulatory affairs are the final stamp for our products and we are keen to maintain it at the highest standard. I am proud of the experience, know-how and knowledge we have aquired over the years working with all the major health authorities and bringing NexoBrid to burn patients worldwide."
Director of Regulatory Affairs
"Quality is a crucial component of becoming an excellent organization. It is what enable us to provide the value with assuring the quality of our products and the safeness of our patients"
VP Quality
Chairman of the Board of Directors
Board Member
Steve has served as a member of our board of directors since May 2017 and as Chairman of our board since October 2017 until August 2022. since August 2022 Steve serves as a member of our board of directors. Mr. Wills has served, since 1997, as the Executive Vice President, Secretary, Treasurer and Chief Financial Officer of Palatin Technologies, Inc. ("Palatin"), a publicly‑held biopharmaceutical company developing targeted, receptor‑specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential. He has served in various roles at Palatin since 2017, including as Executive Vice President of Operations from 2005 until June 2011 and as and as Chief Operating Officer and Executive Vice President from 2011 to present. Mr. Wills served as Executive Chairman and Interim Principal Executive Officer of Derma Sciences, Inc. ("Derma"), a publicly‑held company providing advanced wound care products, from December 2015 until February 2017 when Derma was acquired by Integra Lifesciences Holdings Corporation. Mr. Wills also served as the lead director and chairman of the audit committee until February 2017 and as Derma Chief Financial Officer from 1997 to 2000. Mr. Wills serves on the board of trustees and executive committee of The Hun School of Princeton since 2013, and its chairman since June 2018. From 1991 to 2000 Mr. Wills was the president and Chief Operating Officer of Golomb, Wills & Company, P.C., a public accounting firm. Mr. Wills, a certified public accountant, received his B.S in accounting from West Chester University, and a M.S. in taxation from Temple University.
Board Member
Board Member
Board Member
Board Member
Board Member
Board Member
Sharon has served as a member of our board of directors since July 2022. Sharon served as our Chief Executive Officer since May 2019. Prior to that time, he served as our Chief Financial and Operations Officer, beginning in April 2007. From 2002 to 2007, Mr. Malka was a partner at Variance Economic Consulting Ltd., a multi‑disciplinary consulting boutique that specializes in financial and business services. Mr. Malka also served as a Senior Manager at Kesselman Corporate Finance, a division of PricewaterhouseCoopers Global Network, from 1998 to 2002. Mr. Malka holds a B.Sc. in Business Administration from the Business Management College in Israel and an M.B.A. from Bar Ilan University, Israel.
Co-founder and CEO of Equashield, a leading global provider of hazardous drug compounding technologies
Recently collaborated with Nordic Capital in a deal valued at $1.3 billion. He also founded Biopharmax, a global design and construction provider of manufacturing facilities and systems for biotechnology, pharmaceutical and synthesis API manufacturers. Mr. Shem-Tov will provide MediWound with his expertise in scaling up facilities and optimizing manufacturing processes.
Venture Partner at aMoon, Israel’s largest HealthTech VC fund
Mr. Moed has recently retired from Bristol Myers Squibb (BMS), as Senior Vice President, Corporate Strategy. He led the strategic direction of the company with close linkage to all its major businesses, functions, and geographies. His recent focus was on the $90 billion acquisition and integration of Celgene by BMS. He serves in Board and advisory roles supporting companies in the HealthTech sector. Mr. Moed with his experience as an executive in the life sciences industry will provide MediWound with his expertise in strategic development for life science innovations.
Chief of Surgery at Mount Sinai West Hospital in New York, practices as a senior vascular surgeon
He holds the academic title of Professor of Surgery at the Icahn School of Medicine. He is a world leader in limb salvage and lower extremity wound healing. To date, he has been the principal investigator on over 70 clinical trials. He directs a clinical research program in the field of lower extremity wound healing and tissue repair and published extensively. He currently sits on the editorial board of WOUNDS and is a reviewer for other journals. Dr. Lantis will provide MediWound with his medical expertise in all aspects of wound care.